These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
643 related articles for article (PubMed ID: 16256870)
21. Association of asymmetric dimethylarginine and endothelial dysfunction. Böger RH Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027 [TBL] [Abstract][Full Text] [Related]
22. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Elesber AA; Solomon H; Lennon RJ; Mathew V; Prasad A; Pumper G; Nelson RE; McConnell JP; Lerman LO; Lerman A Eur Heart J; 2006 Apr; 27(7):824-31. PubMed ID: 16434411 [TBL] [Abstract][Full Text] [Related]
23. Accelerated onset of senescence of endothelial progenitor cells in patients with type 2 diabetes mellitus: role of dimethylarginine dimethylaminohydrolase 2 and asymmetric dimethylarginine. Yuan Q; Hu CP; Gong ZC; Bai YP; Liu SY; Li YJ; Jiang JL Biochem Biophys Res Commun; 2015 Mar; 458(4):869-76. PubMed ID: 25701782 [TBL] [Abstract][Full Text] [Related]
24. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Antoniades C; Shirodaria C; Leeson P; Antonopoulos A; Warrick N; Van-Assche T; Cunnington C; Tousoulis D; Pillai R; Ratnatunga C; Stefanadis C; Channon KM Eur Heart J; 2009 May; 30(9):1142-50. PubMed ID: 19297385 [TBL] [Abstract][Full Text] [Related]
25. Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants. Xuan C; Tian QW; Li H; Zhang BB; He GW; Lun LM Eur J Prev Cardiol; 2016 Mar; 23(5):502-10. PubMed ID: 25956428 [TBL] [Abstract][Full Text] [Related]
26. Synergistic effects of asymmetrical dimethyl-L-arginine accumulation and endothelial progenitor cell deficiency on renal function decline during a 2-year follow-up in stable angina. Surdacki A; Marewicz E; Wieczorek-Surdacka E; Rakowski T; Szastak G; Pryjma J; Dudek D; Dubiel JS Nephrol Dial Transplant; 2010 Aug; 25(8):2576-83. PubMed ID: 19729464 [TBL] [Abstract][Full Text] [Related]
27. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. Böger RH J Nutr; 2004 Oct; 134(10 Suppl):2842S-2847S; discussion 2853S. PubMed ID: 15465797 [TBL] [Abstract][Full Text] [Related]
28. [Asymmetric dimethyl arginine (ADMA): a novel cardiovascular risk factor?]. Stühlinger M Wien Med Wochenschr; 2007 Feb; 157(3-4):57-60. PubMed ID: 17340060 [TBL] [Abstract][Full Text] [Related]
30. Endothelial nitric oxide synthase enhancer for protection of endothelial function from asymmetric dimethylarginine-induced injury in human internal thoracic artery. Xuan C; Chang FJ; Liu XC; Bai XY; Liao XL; He GW; Ou JS J Thorac Cardiovasc Surg; 2012 Sep; 144(3):697-703. PubMed ID: 22336756 [TBL] [Abstract][Full Text] [Related]
31. ADMA: its role in vascular disease. Cooke JP Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864 [TBL] [Abstract][Full Text] [Related]
32. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. Böger RH; Bode-Böger SM; Tsao PS; Lin PS; Chan JR; Cooke JP J Am Coll Cardiol; 2000 Dec; 36(7):2287-95. PubMed ID: 11127475 [TBL] [Abstract][Full Text] [Related]
33. Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor. Jiang JL; Jiang DJ; Tang YH; Li NS; Deng HW; Li YJ Acta Pharmacol Sin; 2004 Jul; 25(7):893-901. PubMed ID: 15210062 [TBL] [Abstract][Full Text] [Related]
34. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Jiang JL; Li Ns NS; Li YJ; Deng HW Br J Pharmacol; 2002 Mar; 135(5):1175-82. PubMed ID: 11877324 [TBL] [Abstract][Full Text] [Related]
35. [Differentiation of 2 endothelial progenitor cells in vitro and inhibitory effect of asymmetric dimethylarginine on its proliferation]. He J; Xie XM; Jiang DJ; Fang YQ; Chen XB Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Feb; 33(2):138-45. PubMed ID: 18326908 [TBL] [Abstract][Full Text] [Related]
36. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance. Toutouzas K; Riga M; Stefanadi E; Stefanadis C Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879 [TBL] [Abstract][Full Text] [Related]
37. Asymmetric Dimethylarginine Induced Apoptosis and Dysfunction of Endothelial Progenitor Cells: Role of Endoplasmic Reticulum Stress Pathway. Ye S; Zhou X; Lin J; Chen P Biomed Res Int; 2017; 2017():6395601. PubMed ID: 28589144 [TBL] [Abstract][Full Text] [Related]
38. Globular adiponectin improves high glucose-suppressed endothelial progenitor cell function through endothelial nitric oxide synthase dependent mechanisms. Huang PH; Chen JS; Tsai HY; Chen YH; Lin FY; Leu HB; Wu TC; Lin SJ; Chen JW J Mol Cell Cardiol; 2011 Jul; 51(1):109-19. PubMed ID: 21439968 [TBL] [Abstract][Full Text] [Related]
39. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Böger RH; Bode-Böger SM; Szuba A; Tsao PS; Chan JR; Tangphao O; Blaschke TF; Cooke JP Circulation; 1998 Nov; 98(18):1842-7. PubMed ID: 9799202 [TBL] [Abstract][Full Text] [Related]
40. Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein: effects of aminoguanidine. Yin QF; Fu SH; He P; Xiong Y Atherosclerosis; 2007 Jan; 190(1):53-61. PubMed ID: 16533509 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]